OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis
Authors:
- Joanna C. RobsonJRJoanna C. Robson
- Gunnar TomassonGTGunnar Tomasson
- Nataliya MilmanNMNataliya Milman
- Sue AshdownSASue Ashdown
- Annelies BoonenABAnnelies Boonen
- George C. CaseyGCGeorge C. Casey
- Peter F. CronholmPCPeter F. Cronholm
- David CuthbertsonDCDavid Cuthbertson
- Jill DawsonJDJill Dawson
- Haner DireskeneliHDHaner Direskeneli
- Ebony EasleyEEEbony Easley
- Tanaz A. KermaniTKTanaz A. Kermani
- 1 September 2017
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 44 (10) , 1529-1535
Abstract
Objective.: The antineutrophil cytoplasmic antibody–associated vasculitides (AAV) are multiorgan diseases. Patients with AAV report impairment in their health-related quality of life (HRQOL) and have different priorities regarding disease assessment compared with physicians. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group previously received endorsement for a core set of domains in AAV. Two approaches to measure patient-reported outcomes (PRO) were presented at OMERACT 2016.Methods.: A novel 5-step tool was used to facilitate assessment of the instruments by delegates: the OMERACT Filter 2.0 Instrument Selection Algorithm, with a red-amber-green checklist of questions, including (1) good match with domain (face and content validity), (2) feasibility, (3) do numeric scores make sense (construct validity)?, (4) overall ratings of discrimination, and (5) can individual thresholds of meaning be defined? Delegates gave an overall endorsement. Three generic Patient-Reported Outcomes Measurement Information System (PROMIS) instruments (fatigue, physical functioning, and pain interference) and a disease-specific PRO, the AAV-PRO (6 domains related to symptoms and HRQOL), were presented.Results.: OMERACT delegates endorsed the use of the PROMIS instruments for fatigue, physical functioning, and pain interference (87.6% overall endorsement) and the disease-specific AAV-PRO instrument (89.4% overall endorsement).Conclusion.: The OMERACT Vasculitis Working Group gained endorsement by OMERACT for use of the PROMIS and the AAV-PRO in clinical trials of vasculitis. These instruments are complementary to each other. The PROMIS and the AAV-PRO need further work to assess their utility in longitudinal settings, including their ability to discriminate between treatments of varying efficacy in the setting of a randomized controlled trial.Keywords
This publication has 24 references indexed in Scilit:
- Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's)Arthritis Care & Research, 2011
- The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated VasculitisThe Journal of Rheumatology, 2011
- Health‐related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody–associated vasculitisArthritis Care & Research, 2011
- Measuring fatigue in rheumatoid arthritis: A cross‐sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi‐Dimensional questionnaire, visual analog scales, and numerical rating scalesArthritis Care & Research, 2010
- Patient‐reported outcome assessment in vasculitis may provide important data and a unique perspectiveArthritis Care & Research, 2010
- The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008Journal of Clinical Epidemiology, 2010
- Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9The Journal of Rheumatology, 2009
- Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)Arthritis & Rheumatism, 2005
- Development of ICF Core Sets for patients with chronic conditionsJournal of Rehabilitation Medicine, 2004
- A Comparative Review of Generic Quality-of-Life InstrumentsPharmacoEconomics, 2000